Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix
Objective This study elucidated the efficacy of Relugolix (REL) on the reduction of uterine volume and clinical symptoms for the treatment of adenomyosis.Methods We conducted a retrospective cohort study of patients who received REL (40 mg for about 20 weeks) and who underwent a hysterectomy for ade...
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Taylor & Francis Group
2023-12-01
|
| Edice: | Gynecological Endocrinology |
| Témata: | |
| On-line přístup: | https://www.tandfonline.com/doi/10.1080/09513590.2023.2237121 |